Viking Therapeutics Stock News

Viking Therapeutics benefitted indirectly from a big-ticket buyout of a peer. Roche could end up paying over $3 billion in that deal.

Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading candidates are currently in phase 2 clinical trials.

Viking Therapeutics (NASDAQ: VKTX ) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. This data comes from its Phase 1 study of VK2735

Viking Therapeutics (NASDAQ:VKTX) shares shot up 12% in overnight US trading as the drug developer revealed more impressive trial data from a treatment utilising GLP-1 receptors. Data from the phase 1

Viking Therapeutics Inc. VKTX, -0.37% shares rose in the extended session Tuesday after the biotech drug developer said data from an early stage clinical study showed its drug candidate reduced liver

SAN DIEGO , Sept. 7, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an

Investors always hope to buy low and sell high. In order to do so, it's necessary to identify stocks that are undervalued.

The stock of biotech Viking Therapeutics Inc. was up 4% Wednesday to extend its week-to-date gains to 13%, after positive news on Novo Nordisk's obesity drugs reducing the risk of cardio events ignite

Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.

Growth stocks have returned to form this year. Roivant Sciences and Viking Therapeutics are two growth plays that should interest risk-tolerant investors.

Vertex Pharmaceuticals' strong pipeline is positioning the company for the future. Viking Therapeutics' stock is soaring as the market anticipates its candidate drugs hitting the marketplace.

Hims & Hers has a booming telemedicine business that could grow by 57% this year. Viking Therapeutics has a promising pipeline that features a couple of potential blockbuster drugs.

Momentum stocks offer investors the opportunity to capitalize on strong and continued upward price changes. At the same time, it is an inherently and undeniably risky trading method.

Now is a great time to accumulate top undervalued biotech stocks. For one, the sector is recession-proof.

Viking and Nano-X are up-and-comers in healthcare with exciting products in the works. However, neither business is profitable, and it could be years before either one is.